Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma

This page shows the latest Kite Pharma news and features for those working in and with pharma, biotech and healthcare.

Yescarta gains first FDA approval for indolent follicular lymphoma

Yescarta gains first FDA approval for indolent follicular lymphoma

First CAR-T cell therapy to be approved in this indication. Gilead subsidiary Kite's Yescarta has been granted accelerated approval from the US Food and Drug Administration (FDA) for indolent ... Kite also recently revealed some positive data for

Latest news

More from news
Approximately 16 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    Many other companies built similarly robust immunology and oncology portfolios. In response to this success, some Big Pharma companies have reorganised their operations to include new business units dedicated solely to ... and. CAR-T therapies.

  • The good, the bad and the ugly The good, the bad and the ugly

    The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... The data this article was based on is available in full online:

  • Pharma deals continue to slide Pharma deals continue to slide

    Given big pharma’s reluctance to spend on M&A it is perhaps surprising that this month Gilead has announced the $11.9bn acquisition of Kite Pharma. ... Licensing  . The most common licensing deal is big pharma licensing in from biotech.

  • Deal Watch January 2017 Deal Watch January 2017

    Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19). ... 160. Kite Pharma. Fosun Pharma. Formation of a JV. Autologous T-cell therapies in cancer.

  • Deal Watch November 2016 Deal Watch November 2016

    As Juno wrestles with bad publicity and a depressed share price, Novartis and Kite Pharma, also active in the CAR T cell space, presented promising data at the ASH meeting for ... licence. 115.5. Medivir | BioPhausia/ Karo Pharma. business with 13

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Understanding the evolving CAR-T market

    Big pharma also wanted a slice of the action. Aggressive deal-making quickly became central to the rise of CAR-T, with Gilead acquiring Kite Pharma for a mammoth $11.9bn ... So, what does pharma need to do to avoid being overtaken by the competition and

  • How do you define a biotech company?

    Johnson &Johnson and Pfizer are two of the largest pharma companies in the world by revenue but both have numerous biological therapies. ... This approach is particularly apparent in some of the recent examples of technology pioneered by biotech

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...